2. Antibody-drug Conjugate/ADC Related Immunology/Inflammation
  3. Radionuclide-Drug Conjugates (RDCs) PSMA
  4. PDI2

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PDI2

PDI2 Chemical Structure

CAS No. : 3110124-60-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PDI2 Related Antibodies

Top Publications Citing Use of Products

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer[1].

In Vitro

[111In]In-PDI2 (0.195-50 nM; incubated on ice for 2 h) binds specifically to PSMA on LNCaP cells, with a Kd value of 22.8 nM[1].
[111In]In-PDI2 (37 kBq; incubated on ice for 2 h, incubated at 37°C for 0-4 h) shows an internalization rate of 38.9% in LNCaP cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDI2 Related Antibodies
In Vivo

PDI2 (111 kBq; i.v.; single dose) exhibits high and persistent tumor uptake in the PSMA-positive LNCaP prostate cancer xenograft model, along with a favorable tumor-to-kidney radioactivity ratio[1].
PDI2 (5-10 kBq; i.v.; single dose) effectively inhibits the growth of PSMA-positive LNCaP prostate cancer xenografts with no obvious toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nu/nu (male, 5-6 weeks old)[1]
Dosage: 111 kBq
Administration: i.v.; single dose
Result: Measured 20.74% ID/g tumor accumulation at 4-h postinjection; measured 25.47% ID/g tumor accumulation at 24-h postinjection; measured 13.54% ID/g tumor accumulation at 96-h postinjection; measured 52.31% ID/g renal uptake at 4-h postinjection; measured 4.85% ID/g renal uptake at 24-h postinjection; achieved 7.3 tumor-to-kidney radioactivity ratio.
Molecular Weight

1271.41

Formula

C59H90N12O19
CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PDI2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDI23110124-60-9PSMA-DOTA-PEI2PDI 2PDI-2Radionuclide-Drug Conjugates (RDCs)PSMAProstate-specific membrane antigenPSMA-positive LNCaP prostate cancer xenograftsSPECT/CTprostate-specific membrane antigenmetastatic castration-resistant prostate cancerprostate cancerprostate cancer cellstargeted radionuclide therapyLNCaP cellsclathrin-dependent endocytosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDI2
Cat. No.:
HY-P11591
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.